German virologist
Ralf M. Altmeyer is a German virologist who leads the Institut Pasteur of Shanghai,[1] a joint institute of the Chinese Academy of Sciences, Institut Pasteur and Shanghai Municipal Government, founded in 2004.
He completed his pre-doctoral studies at the State University of New York at Stony Brook, and holds a Ph. D. (1994) from Institut Pasteur in Paris, where he also completed his postdoctoral thesis on neuropathogenesis of HIV infections (1996).[citation needed]
His research interests including respiratory diseases, Hepatitis C, HIV, and focus on anti-infective therapeutic strategies.[citation needed]
During his career of fifteen years at Institut Pasteur and the Pasteur international network, Ralf Altmeyer held various management positions including the position of CEO of the HKU-Pasteur Research Centre in Hong Kong. From 2003 to 2006 Ralf Altmeyer was the architect of a successful restructuring and establishment of the organization's new strategy.[2]
He left Institut Pasteur in 2006 to become the President of CombinatoRx-Singapore,[3] the infectious disease subsidiary of CombinatoRx (NASDAQ:CRXX), established in 2005 in collaboration with Bio*One Capital in Singapore. Ralf Altmeyer left CombinatoRx-Singapore in summer 2009 subsequent to the acquisition of the company by Forma Therapeutics. In 2011, he founded Advance BioChina, a Shanghai-based incubator company that helps global biotech companies access the Chinese market.
Ralf Altmeyer also holds the position of adjunct professor at Griffith University of Australia, Institute of Glycomics.[4]
References
